Pharma III – Pharmaceutical and Biotech Regulation and Innovation

Course content

The course will give the participants knowledge on how to move research towards a commercial setting by connecting and learning from industry players, biotech, start-ups, and venture capital from the Danish innovation ecosystem. The course will provide insights on how to secure IP, legals, and financing in the early phases. The course will also provide insights on critical issues for translating research into either products (medtech and drugs primarily) or start-ups, and on decision processes for progressing research either in industry or start-ups.


The course will include lectures, site-visits and discussions with key industry players from both speciality pharma companies (for instance Novo Nordisk and Lundbeck), biotech companies (for instance Galecto and IO-Biotech), and start-ups primarily from BioInnovation Institute and COBIS.


BRIDGE - Translational Excellence Programme

Learning outcome

Upon completing the course, participants should be able to:



  • Understand how the organizational set-up supports how projects are prioritized in pharmaceutical and biotech companies.
  • Understand the rationale behind key business processes in the pharmaceutical and biotech industry - and how to move research from academia into start-ups or existing companies.
  • Gain an insight into the Danish innovation ecosystem and its possibilities.
  • Basic knowledge on legal concepts that needs to be addressed while setting up a start-up company.


  • Describe the process of evaluating research results and securing IP rights, how to secure financing in the early phases, and key research and business concepts in building a start-up based on translational research or in the collaboration with biotech or pharma.


  • Explain the rationale behind a project management portfolio, including how companies decide from a pool of competing projects to create a profitable portfolio that achieve the company’s strategic goals.
  • Discuss and understand commercial decision structures in pharmaceutical and biotech companies and start-ups.
  • Discuss and understand potential factors influencing the IP, legal and financing processes from research lab to start-up company or license agreement with an established company.

Site visits, lectures, and discussions.

The course will end with an evaluation where participants must reflect on course learning outcomes and give feedback for course development.

Course literature will be published on Absalon.

Participants must meet the admission criteria in BRIDGE - Translational Excellence Programme.

Continuous feedback during the course of the semester
Type of assessment
Continuous assessment
Course participation
Type of assessment details
Attendance and active participation
All aids allowed
Marking scale
passed/not passed
Censorship form
No external censorship
Criteria for exam assessment

Active contribution and course participation according to the BRIDGE Guidelines and Practicalities.

Part time Master and Diploma courses

  • Category
  • Hours
  • Lectures
  • 2
  • Preparation
  • 4
  • Excursions
  • 15
  • English
  • 21


Course number
Programme level
Part Time Master
See course dates and course programme in Absalon.

*This course is offered in spring 2024 for the BRIDGE 2022-2024 programme.
** This course is offered in spring 2025 for the BRIDGE 2023-2025 programme.
15 participants
Study Board for the Professionel Master´s Degree Programmes at The Faculty og Health and Medical Science
Contracting department
  • Department of Biomedical Sciences
Contracting faculty
  • Faculty of Health and Medical Sciences
Course Coordinator
  • Trine Winterø   (6-7e7c738173784a7d7f786e38757f386e75)
Saved on the 05-07-2023

Are you BA- or KA-student?

Are you bachelor- or kandidat-student, then find the course in the course catalog for students:

Courseinformation of students